Drug
TLK286
TLK286 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 6 completed trials
Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
3
50%
Ph phase_1
3
50%
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
6 of 6 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(6)
Detailed Status
Completed6
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (50.0%)
Phase 23 (50.0%)
Trials by Status
completed6100%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_1
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT00088556
completedphase_1
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
NCT00051948
completedphase_2
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
NCT00040638
completedphase_2
Phase 2 Study of TLK286 in Metastatic Breast Cancer
NCT00035841
completedphase_1
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
NCT00052065
Clinical Trials (6)
Showing 6 of 6 trials
NCT00088556Phase 1
Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT00051948Phase 1
TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
NCT00040638Phase 2
Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer
NCT00035841Phase 2
Phase 2 Study of TLK286 in Metastatic Breast Cancer
NCT00052065Phase 1
TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
NCT00038428Phase 2
Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6